Literature DB >> 33269376

C1QTNF6 regulates cell proliferation and apoptosis of NSCLC in vitro and in vivo.

Wei Zhang1, Ganzhu Feng2.   

Abstract

OBJECTIVES: Lung cancer has been reported as the leading cause of cancer-associated deaths in humans, and its incidence continues to increase in the world. A growing number of studies have shown that dysregulated genes are associated with the occurrence and poor prognosis of a variety of tumors, including non-small cell lung cancer (NSCLC). C1q/tumor necrosis factor-related protein 6 (C1QTNF6), a member of the C1q/tumor necrosis factor-related protein (CTRP) family, has been revealed to play a role in carcinogenesis and cancer progression. Nevertheless, the effects and mechanisms of C1QTNF6 in NSCLC remain unrevealed.
MATERIALS AND METHODS: MTT (3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide) and colony formation, flow cytometric and transwell assays were performed to explore the cell function. Real-time PCR (RT-PCR) and Western blot were used to analyze the mRNA and protein expression.
RESULTS: In the present study, we found that C1QTNF6 significantly promoted the proliferation of SPCA1 and A549 cells by MTT and colony formation assays. In addition, down-regulation of C1QTNF6 weakened the tumor growth in vivo. Besides, C1QTNF6 remarkably reduced apoptosis by flow cytometric analysis and TUNEL assay. Furthermore, the capability of migration and invasion was obviously enhanced on C1QTNF6 overexpression.
CONCLUSION: Overall, our results demonstrated that inhibition of C1QTNF6 attenuated cell proliferation, migration, invasion and promoted apoptosis in vitro and in vivo of NSCLC. Based on the above results, our study provided us with a new and key perspective in understanding and treating NSCLC.
© 2021 The Author(s).

Entities:  

Keywords:  C1QTNF6; NSCLC; apoptosis; proliferation

Mesh:

Substances:

Year:  2021        PMID: 33269376      PMCID: PMC7805025          DOI: 10.1042/BSR20201541

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  27 in total

Review 1.  C1q and its growing family.

Authors:  Rohit Ghai; Patrick Waters; Lubka T Roumenina; Mihaela Gadjeva; Mihaela S Kojouharova; Kenneth B M Reid; Robert B Sim; Uday Kishore
Journal:  Immunobiology       Date:  2006-12-12       Impact factor: 3.144

2.  Metastasis of Colon Cancer in the External Auditory Meatus.

Authors:  Jamal Huseynov; Christian Mozet; Milos Fischer
Journal:  Dtsch Arztebl Int       Date:  2019-04-12       Impact factor: 5.594

3.  Knockdown of CTRP6 inhibits adipogenesis via lipogenic marker genes and Erk1/2 signalling pathway.

Authors:  Wen-jing Wu; De-lin Mo; Cun-zhen Zhao; Chen Zhao; Yao-sheng Chen; Wei-jun Pang; Gong-she Yang
Journal:  Cell Biol Int       Date:  2015-02-02       Impact factor: 3.612

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma.

Authors:  Changxia Shao; Chuanwen Lu; Lixia Chen; Patrick P Koty; Everardo Cobos; Weimin Gao
Journal:  Cancer Chemother Pharmacol       Date:  2010-08-28       Impact factor: 3.333

Review 6.  From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.

Authors:  Avi Ashkenazi; Wayne J Fairbrother; Joel D Leverson; Andrew J Souers
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

Review 7.  Lung cancer: current therapies and new targeted treatments.

Authors:  Fred R Hirsch; Giorgio V Scagliotti; James L Mulshine; Regina Kwon; Walter J Curran; Yi-Long Wu; Luis Paz-Ares
Journal:  Lancet       Date:  2016-08-27       Impact factor: 79.321

Review 8.  Understanding and targeting resistance mechanisms in NSCLC.

Authors:  Julia Rotow; Trever G Bivona
Journal:  Nat Rev Cancer       Date:  2017-10-25       Impact factor: 60.716

9.  [C1q tumor necrosis factor-related protein 6 (CTRP6) inhibits the proliferation and migration of ovarian cancer cells].

Authors:  Lin Wang; Zidong Liu; Lili Duan; Binfang Ma; Zhe Sun
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2015-12

Review 10.  MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer.

Authors:  Qun Zhou; Shao-Xin Huang; Feng Zhang; Shu-Jun Li; Cong Liu; Yong-Yong Xi; Liang Wang; Xin Wang; Qi-Qiang He; Cheng-Cao Sun; De-Jia Li
Journal:  Cell Prolif       Date:  2017-10-08       Impact factor: 6.831

View more
  6 in total

1.  Angiogenic Factor-Based Signature Predicts Prognosis and Immunotherapy Response in Non-Small-Cell Lung Cancer.

Authors:  Xinpei Gu; Liuxi Chu; Yanlan Kang
Journal:  Front Genet       Date:  2022-05-18       Impact factor: 4.772

2.  Homeobox A1 Facilitates Immune Escape and Alleviates Oxidative Stress in Lung Adenocarcinoma.

Authors:  Fen Zhao; Hui Tian; Xinchao Liu; Yuanxiazi Guan; Ying Zhu; Peng Ren; Jianbo Zhang; Yinjun Dong; Lei Fu
Journal:  Oxid Med Cell Longev       Date:  2022-05-19       Impact factor: 7.310

3.  C1QTNF6 promotes oral squamous cell carcinoma by enhancing proliferation and inhibiting apoptosis.

Authors:  Xiaobin Song; Longjie Li; Liang Shi; Xinyu Liu; Xun Qu; Fengcai Wei; Ketao Wang
Journal:  Cancer Cell Int       Date:  2021-12-14       Impact factor: 5.722

4.  C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis.

Authors:  Wei Liu; Jian Zhang; Tao Xie; Xiaoting Huang; Baiyao Wang; Yunhong Tian; Yawei Yuan
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

5.  A Novel Secreted Protein-Related Gene Signature Predicts Overall Survival and Is Associated With Tumor Immunity in Patients With Lung Adenocarcinoma.

Authors:  Shuaijun Chen; Jun Zhang; Qian Li; Lingyan Xiao; Xiao Feng; Qian Niu; Liqin Zhao; Wanli Ma; Hong Ye
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

6.  C1QTNF6 regulated by miR-29a-3p promotes proliferation and migration in stage I lung adenocarcinoma.

Authors:  Guofu Lin; Lanlan Lin; Hai Lin; Yingxuan Xu; Wenhan Chen; Yifei Liu; Jingyang Wu; Shaohua Chen; Qinhui Lin; Yiming Zeng; Yuan Xu
Journal:  BMC Pulm Med       Date:  2022-07-25       Impact factor: 3.320

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.